Immune tolerance strategies in siblings with infantile Pompe disease - Advantages for a preemptive approach to high-sustained antibody titers

Molecular Genetics and Metabolism Reports

Volumn 4, Issue , 2015, Pages 30-34

  Stenger, Elizabeth O ^a   Kazi, Zoheb ^b   Lisi, Emily ^c   Gambello, Michael J ^c   Kishnani, Priya ^b  

^a EMORY UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bortezomib; High sustained antibody titers; Immune tolerance induction; Infantile Pompe disease

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN G; METHOTREXATE; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RITUXIMAB;

AFRICAN AMERICAN; ALLELE; ANTIBODY TITER; ARTICLE; ASSISTED VENTILATION; CASE REPORT; DISEASE COURSE; DRUG USE; ENZYME REPLACEMENT; EXTUBATION; FOLLOW UP; GENETIC SCREENING; GLYCOGEN STORAGE DISEASE TYPE 2; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMMUNE RESPONSE; IMMUNE TOLERANCE INDUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFANT DISEASE; INFANTILE POMPE DISEASE; MACROGLOSSIA; MALE; MOTOR DEVELOPMENT; MUSCLE HYPOTONIA; NASOGASTRIC TUBE; NEUTROPHIL COUNT; NEWBORN; NONSENSE MUTATION; RECURRENT ASPIRATION; RESPIRATORY FAILURE; SIBLING; STOMACH TUBE; SUPRAVENTRICULAR TACHYCARDIA; TRACHEOSTOMY; TREATMENT DURATION; VIRAL RESPIRATORY TRACT INFECTION; WESTERN BLOTTING; WOLFF PARKINSON WHITE SYNDROME;

EID: 84935914383     PISSN: None     EISSN: 22144269     Source Type: Journal    
DOI: 10.1016/j.ymgmr.2015.05.004     Document Type: Article

References (27)

1. P.S. Kishnani, R.D. Steiner, D. Bali, K. Berger, and et al. Pompe disease diagnosis and management guideline Genet Med 8 2006 267 288 Disease AWGoMoP
2. P.S. Kishnani, M. Nicolino, T. Voit, R.C. Rogers, A.C. Tsai, and et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease J Pediatr 149 2006 89 97
3. A. Amalfitano, A.R. Bengur, R.P. Morse, J.M. Majure, L.E. Case, and et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial Genet Med 3 2001 132 138
4. H.M. van den Hout, W. Hop, O.P. van Diggelen, J.A. Smeitink, G.P. Smit, and et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature Pediatrics 112 2003 332 340
5. P.S. Kishnani, W.L. Hwu, H. Mandel, M. Nicolino, F. Yong, and et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease J Pediatr 148 2006 671 676
6. P.S. Kishnani, D. Corzo, M. Nicolino, B. Byrne, H. Mandel, and et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease Neurology 68 2007 99 109
7. P.S. Kishnani, D. Corzo, N.D. Leslie, D. Gruskin, A. Van der Ploeg, and et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease Pediatr Res 66 2009 329 335
8. M. Nicolino, B. Byrne, J.E. Wraith, N. Leslie, H. Mandel, and et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease Genet Med 11 2009 210 219
9. S.N. Prater, S.G. Banugaria, S.M. DeArmey, E.G. Botha, E.M. Stege, and et al. The emerging phenotype of long-term survivors with infantile Pompe disease Genet Med 14 2012 800 810
10. J. Wang, J. Lozier, G. Johnson, S. Kirshner, D. Verthelyi, and et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment Nat Biotechnol 26 2008 901 908
11. S.G. Banugaria, S.N. Prater, Y.K. Ng, J.A. Kobori, R.S. Finkel, and et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease Genet Med 13 2011 729 736
12. Myozyme (2006) [Package Insert ]. Cambridge (MA): Genzyme Corporation.
13. S.G. Banugaria, T.T. Patel, J. Mackey, S. Das, A. Amalfitano, and et al. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells Mol Genet Metab 105 2012 677 680
14. P.S. Kishnani, P.C. Goldenberg, S.L. DeArmey, J. Heller, D. Benjamin, and et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants Mol Genet Metab 99 2010 26 33
15. T.T. Patel, S.G. Banugaria, L.E. Case, S. Wenninger, B. Schoser, and et al. The impact of antibodies in late-onset Pompe disease: a case series and literature review Mol Genet Metab 106 2012 301 309
16. N.J. Mendelsohn, Y.H. Messinger, A.S. Rosenberg, and P.S. Kishnani Elimination of antibodies to recombinant enzyme in Pompe's disease N Engl J Med 360 2009 194 195
17. Y.H. Messinger, N.J. Mendelsohn, W. Rhead, D. Dimmock, E. Hershkovitz, and et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease Genet Med 14 2012 135 142
18. P.G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, and et al. A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2003 2609 2617
19. K. Neubert, S. Meister, K. Moser, F. Weisel, D. Maseda, and et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis Nat Med 14 2008 748 755
20. E. Gazzerro, S. Assereto, A. Bonetto, F. Sotgia, S. Scarfi, and et al. Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies Am J Pathol 176 2010 1863 1877
21. B.C. Beehler, P.G. Sleph, L. Benmassaoud, and G.J. Grover Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation Exp Biol Med (Maywood) 231 2006 335 341
22. S.G. Banugaria, S.N. Prater, J.K. McGann, J.D. Feldman, J.A. Tannenbaum, and et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease Genet Med 15 2013 123 131
23. M. Kroos, R.J. Pomponio, L. van Vliet, R.E. Palmer, M. Phipps, and et al. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating Hum Mutat 29 2008 E13 E26
24. M. Vogel, W. Staller, and K. Buhlmeyer Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants, and children Pediatr Cardiol 12 1991 143 149
25. J.M. de Vries, N.A. van der Beek, M.A. Kroos, L. Ozkan, P.A. van Doorn, and et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase Alfa Mol Genet Metab 101 2010 338 345
26. T.E. Hunley, D. Corzo, M. Dudek, P. Kishnani, A. Amalfitano, and et al. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease Pediatrics 114 2004 e532 e535
27. W.E. Smith, J.A. Sullivan-Saarela, J.S. Li, G.F. Cox, D. Corzo, and et al. Sibling phenotype concordance in classical infantile Pompe disease Am J Med Genet A 143A 2007 2493 2501